title: Anionic- and lipophilic-mediated surface binding inhibitors of human leukocyte elastase.
abstract: We report the synthesis of a series of diphenylmethane-based oligomers containing anionic and lipophilic functionalities that are potent inhibitors of human leukocyte elastase (HLE). The enzyme inhibition is regulated by the size of the oligomer, as well as, the number of charges. Lipophilicity is an important element in determining potency and specificity against other basic enzymes. Compounds whose scaffolds contain three phenoxyacetic acid groups and three alkyl ethers are competitive and specific inhibitors of HLE with Ki = 20 nM. The mechanism of action of this class of compounds is believed to involve multidendate interactions with the surface of HLE near the active site which prevents substrate access to the catalytic site.
authors.affiliation: Department of Medicinal Chemistry, Rhône-Poulenc Rorer, Collegeville, Pennsylvania 19426, USA.
authors.forename: J
authors.initials: J
authors.lastname: Regan
authors.forename: D
authors.initials: D
authors.lastname: McGarry
authors.forename: J
authors.initials: J
authors.lastname: Bruno
authors.forename: D
authors.initials: D
authors.lastname: Green
authors.forename: J
authors.initials: J
authors.lastname: Newman
authors.forename: C Y
authors.initials: CY
authors.lastname: Hsu
authors.forename: J
authors.initials: J
authors.lastname: Kline
authors.forename: J
authors.initials: J
authors.lastname: Barton
authors.forename: J
authors.initials: J
authors.lastname: Travis
authors.forename: Y M
authors.initials: YM
authors.lastname: Choi
authors.forename: F
authors.initials: F
authors.lastname: Volz
authors.forename: H
authors.initials: H
authors.lastname: Pauls
authors.forename: R
authors.initials: R
authors.lastname: Harrison
authors.forename: A
authors.initials: A
authors.lastname: Zilberstein
authors.forename: S A
authors.initials: SA
authors.lastname: Ben-Sasson
authors.forename: M
authors.initials: M
authors.lastname: Chang
mesh_terms: D001559:Benzhydryl Compounds / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D001665:Binding Sites; D001667:Binding, Competitive; D001798:Blood Proteins / Q000378:metabolism / Q000494:pharmacology; D056649:Cathepsin G; D002403:Cathepsins / Q000037:antagonists & inhibitors; D004791:Enzyme Inhibitors / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D006801:Humans; D007700:Kinetics; D019272:Leukocyte Elastase / Q000037:antagonists & inhibitors*; D015394:Molecular Structure; D009842:Oligopeptides / Q000494:pharmacology; D010642:Phenoxyacetates / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D011761:Pyrrolidonecarboxylic Acid / Q000031:analogs & derivatives; D012697:Serine Endopeptidases; D013917:Thrombin / Q000037:antagonists & inhibitors
chemical_list: D001559:Benzhydryl Compounds; D001798:Blood Proteins; D004791:Enzyme Inhibitors; D009842:Oligopeptides; D010642:Phenoxyacetates; C039741:S 2484; D002403:Cathepsins; D012697:Serine Endopeptidases; C534094:CTSG protein, human; D056649:Cathepsin G; D019272:Leukocyte Elastase; D013917:Thrombin; D011761:Pyrrolidonecarboxylic Acid